摘要:
In certain aspects the invention features novel compositions and pharmaceutical preparations of the same. In certain embodiments, the compositions comprise α- and/or β-boswellic acid and/or their C-acetates in an amount greater than 65% by weight.
摘要:
An aspect of the present invention relates to compositions comprising a gingerol, for example, compositions comprising gingerol in an amount greater than about 2% by weight. In some aspects of the invention, the composition comprises 6-gingerol, 8-gingerol, 10-gingerol, 6-shagaol, or combinations thereof. Another aspect of the invention relates to a method for extracting a ginger species comprising, sequentially extracting a ginger species plant material to yield an essential oil fraction, a gingerol fraction, a phenolic fraction, and a polysaccharide fraction, wherein the essential oil and gingerol fractions are derived by extracting plant feedstock material by supercritical carbon dioxide extraction, the phenolic fraction is extracted from the plant feedstock material or from the remainder of the essential oil and gingerol extractions by hydroalcoholic extraction, and the polysaccharide fraction is derived by water extraction of the remainder of the phenolic extraction.
摘要:
The present invention relates to extracts of curcuma species plant material using supercritical CO2 extraction methods, methods of treating a subject suffering from suffering from amyloid plaque aggregation or fibril formation associated with, for example, Alzheimer's disease, and methods of inhibiting amyloid plaque aggregation or fibril formation in tissue thereof.
摘要:
The present invention comprises methods for making compositions derived from Ilex species, particularly Ilex paraguariensis, having lowered caffeine and tannin concentrations, compositions made by such methods, oral delivery formulations, and methods of use of such compositions. In particular, the present invention comprises methods for making maté compositions that have a predetermined characeteristic, such as a lowered amount of caffeine, elevated amounts of caffeoyls, and/or lowered amounts of tannin compounds compared to the native maté plant materials. Further, the invention comprises methods of additional processing steps tp produce compositions having a predetermined alkaloid ratio or profiles to meet particular considerations for final products. The compositions of the present invention may be processed for specific uses such as tablets or other oral delivery vehicles. These compositions may be used in methods for treatment of physiological and medical conditions.
摘要:
The present invention comprises methods for making compositions derived from Ilex species, particularly Ilex paraguariensis, having lowered caffeine and tannin concentrations, compositions made by such methods, oral delivery formulations, and methods of use of such compositions. In particular, the present invention comprises methods for making maté compositions that have a predetermined characeteristic, such as a lowered amount of caffeine, elevated amounts of caffeoyls, and/or lowered amounts of tannin compounds compared to the native maté plant materials. Further, the invention comprises methods of additional processing steps to produce compositions having a predetermined alkaloid ratio or profiles to meet particular considerations for final products. The compositions of the present invention may be processed for specific uses such as tablets or other oral delivery vehicles. These compositions may be used in methods for treatment of physiological and medical conditions.
摘要:
A multi-level amplifier including a converter circuit being supplied with a supply voltage and operable to generate at least two output voltages, a voltage comparator circuit adapted to compare each of the output voltages with the supply voltage to generate a driving signal, and an amplifier circuit being supplied with an analog input signal, the amplifier circuit including an analog-to-digital converter coupled to a power stage driver and power stage, wherein the power stage driver receives the driving signal from the voltage comparator.
摘要:
Various system embodiments comprise at least one sensor input adapted to receive at least one sensed signal associated with a tachyarrhythmia, a feature set extractor adapted to extract at least two features from the at least one sensed signal associated with the tachyarrhythmia, a feature set generator adapted to form a feature set using the at least two features extracted by the feature set extractor, at least one generator adapted for use to selectively apply an anti-tachycardia pacing (ATP) therapy and a neural stimulation (NS) therapy, and a controller adapted to respond to the feature set. The controller is adapted to initiate the NS therapy when the feature set corresponds to criteria for applying the NS therapy to modify the tachyarrhythmia, and initiate the ATP therapy to terminate the modified tachyarrhythmia. Other aspects and embodiments are provided herein.
摘要:
A multi-level amplifier including a converter circuit being supplied with a supply voltage and operable to generate at least two output voltages, a voltage comparator circuit adapted to compare each of the output voltages with the supply voltage to generate a driving signal, and an amplifier circuit being supplied with an analog input signal, the amplifier circuit including an analog-to-digital converter coupled to a power stage driver and power stage, wherein the power stage driver receives the driving signal from the voltage comparator.
摘要:
A cardiac rhythm management (CRM) system includes an implantable medical device that delivers anti-tachyarrhythmia therapies including ATP. When a tachyarrhythmia episode is detected, the implantable medical device analyzes the morphology of a cardiac signal to determine whether and/or when to deliver an ATP therapy. In various embodiments, the implantable medical device produces morphological parameters indicative of the likeliness of success of the ATP therapy and selects an anti-tachyarrhythmia therapy mode based on the morphological parameters. In various embodiments, the implantable medical device also controls the timing of the ATP therapy delivery using morphological features of the cardiac signal to maximize the probability that the ATP therapy is delivered into an ATP window during which a tachyarrhythmia episode can be effectively terminated by pacing.